Cost-utility and budget impact of methylene blue-treated plasma compared to quarantine

Tourcoing — 30 November 2016 – Macopharma is pleased to inform you that a current article, entitled “Cost-utility and budget impact of methylene blue-treated plasma compared to quarantine.” has been recently published in the journal “Blood Transfusion” [1].

The aim of the study was to estimate the budget impact and cost-utility (sometimes known as cost-effectiveness), from a payer perspective, of using THERAFLEX MB-Plasma compared to quarantine plasma (QP) for pathogen and adverse events reduction of transfused plasma in Spain. Different approaches to plasma collection and the costs of both plasma types were considered.

A model simulating the risks of HBV, HCV, HIV, CMV, a WNV-like infection, allergic reactions and FNHTRs achieved was developed. If QP relies on plasma from whole blood collection and passive quarantine, it is less costly than THERAFLEX MB-Plasma. However, if active donor recall is taken into account, THERAFLEX MB-Plasma reduced cost by 50.46 € per patient and was more effective and led to a net savings.

When previously unaccounted for costs are included, THERAFLEX MB-Plasma approaches cost neutrality for whole blood-derived plasma and is cost savings and more cost-effective under any active QP and/or apheresis approach.

Finally, the analysis of THERAFLEX MB-Plasma shows this technology to be more effective in terms of generating additional health benefit for the plasma-transfused patient population than QP regardless of the quarantine system in place.

About Macopharma

Macopharma SA (“Macopharma”) (www.macopharma.com) is an innovator in global healthcare with expertise in the fields of transfusion and infusion. The company has become the largest supplier of in-line leucodereduction filtration sets in Europe, It is expanding its efforts in the fields of respiratory masks and cellular therapy by developing products for cell expansion, in addition to cell/organ processing and freezing. Headquartered in the Lille metropolitan area (France), Macopharma has four manufacturing facilities in Europe and their products are sold into more than 80 countries worldwide. One of Macopharma’s aims is to provide a comprehensive range for the pathogen reduction of infectious agents in plasma, platelets and red cells. This is aligned with Macopharma’s product development strategy of the continuous quest, through partnerships, for improved safety, efficacy, and quality of transfusion, infusion, masks and cellular therapy.

About THERAFLEX MB-Plasma

The THERAFLEX MB-Plasma System has a Class III CE Mark (available for sale in countries where the CE mark is accepted) and is not currently available for sale in the United States. It is a user-friendly in-house treatment for single units of plasma. The GMP-conforming procedure is adapted for the inactivation of FFP from aphaeresis or whole blood plasma. The MB plasma system uses a combination of a membrane filter Plasmaflex PLAS4, (which removes residual leucocytes, red cells, platelets and aggregates, intra-cellular viruses and minimises the amount of microvesicles and microparticles), a dry Methylene Blue pill, visible light and a Blueflex Methylene Blue removal filter.

See www.bloodsafety.macopharma.com, for more information.

1. Babigumira JB, Lubinga SJ, Castro E, Custer B. Cost-utility and budget impact of methylene blue-treated plasma compared to quarantine plasma. Blood Transfus 2016.

« Go back to the list